Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent’s lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib has already exhibited promising early clinical activity and safety in a Phase 1/2 trial in patients with advanced GIST and also has the potential to fill an unmet need for patients living with Systemic Mastocytosis.
Company Details
- Employees
- 234
- Founded
- -
- Address
- 275 Wyman Street,
- Phone
- (617) 843-5032
- in****@****bio.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cogentbio.com
- Keywords
- gastrointestinal stromal tumors (GIST), Oncology, Systemic Mastocytosis, kinase inhibitors.
- HQ
- Waltham, Massachusetts
Cogent Biosciences Questions
Cogent Biosciences's helpline number is (617) 843-5032
Cogent Biosciences's website is cogentbio.com
Cogent Biosciences's LinkedIn profile is https://www.linkedin.com/company/cogentbiosciences
Cogent Biosciences has
234 employees.
View email and phone details for 234
employees at Cogent Biosciences.
Cogent Biosciences's industry is
Biotechnology Research
Cogent Biosciences's top competitors are
Onkure Therapeutics,
Edgewise Therapeutics,
Enveda,
Vertex Pharmaceuticals,
Alnylam Pharmaceuticals,
Enliven Therapeutics,
Viridian Therapeutics, Inc.,
Immunome, Inc.,
Firefly Bio,
Springworks Therapeutics.
Cogent Biosciences's support email address is info@cogentbio.com
Cogent Biosciences's categories are Biotechnology Research
Cogent Biosciences's founding year is 2014
